読み込み中
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
前日終値
$11.61
+$1.61 · +16.10%
日中の時刻はETです。市場データは遅延する場合があります。
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
日中レンジ
現在 $11.61
52週レンジ
現在 $11.61
日中の時刻はETです。市場データは遅延する場合があります。
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
日中レンジ
現在 $11.61
52週レンジ
現在 $11.61
| 指標（USD） | 2025年度 |
|---|---|
| 研究開発 | 1.09億 USD |
| 販売・一般管理 | 4922.7万 USD |
| 営業費用 | 1.58億 USD |
| 受取利息 | 1104.8万 USD |
| 減価償却費と償却費 | 31万 USD |
| 営業利益 | −1.58億 USD |
| 純利益 | −1.49億 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1817.83万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB1314.07万0.01%1853億 USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI1238.39万0.13%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1219.87万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK750.33万0.02%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF742.04万0.01%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO408.68万0.02%180億 USD0.06%$112.66+0.50%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM302.79万5.48%5528.53万 USD0.59%$29.6009+1.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWORoundhill Investments - GLP-1 & Weight Loss ETFOZEMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
